Reply: Impact of Cardio-Renal Syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up

Int J Cardiol. 2018 May 1:258:206. doi: 10.1016/j.ijcard.2018.01.084.

Authors

Albina Nowak¹, Martin Siegenthaler², Mehdi Namdar³, Frank Ruschitzka⁴

Affiliations

¹ Department of Cardiology, University Heart Centre, University Hospital Zurich, Switzerland. Electronic address: albina.nowak@usz.ch.
² Department of Internal Medicine, Cantonal Hospital of St. Gallen, Switzerland.
³ Department of Cardiology, Geneva University Hospital, Switzerland.
⁴ Department of Cardiology, University Heart Centre, University Hospital Zurich, Switzerland.

PMID: 29544933
DOI: 10.1016/j.ijcard.2018.01.084

No abstract available

Publication types

Letter
Comment

MeSH terms

Cardio-Renal Syndrome*
Disease Progression
Fabry Disease*
Follow-Up Studies
Humans
alpha-Galactosidase

Substances

alpha-Galactosidase